Zulma Tovar-Spinoza1, Hoon Choi2. 1. Department of Neurosurgery, SUNY Upstate Medical University, 604 Jacobsen Hall-750 E Adams St, Syracuse, NY, 13210, USA. Tovarspz@upstate.edu. 2. Department of Neurosurgery, SUNY Upstate Medical University, 604 Jacobsen Hall-750 E Adams St, Syracuse, NY, 13210, USA.
Abstract
BACKGROUND: Pediatric low-grade gliomas (LGGs) account for approximately half of all pediatric central nervous system tumors. The low-grade gliomas' first line of treatment is gross total resection. However, when gross total resection is not possible, options for adjuvant therapy are limited. MRI-guided laser ablation (magnetic resonance-guided laser interstitial thermal therapy (MRgLITT)) offers a new option for treatment in selected cases. We present a description of the current MRgLITT technology and an exemplary case-series review of our experience in its use in LGGs. CASE DESCRIPTION: A 19-month-old male was referred to the pediatric neurosurgery clinic with an incidental left temporal lesion discovered on a prenatal ultrasound. An MRI of the brain revealed a diffuse mesial temporal lesion. Electroencephalogram (EEG) showed generalized activity arising from the lesion. The patient underwent a navigation-guided biopsy then, two bolts were secured to the skull, and laser ablation was performed with intraoperative MR guidance. Pathology was consistent with ganglioglioma. Follow-up images 13 months after ablation showed a significant volumetric reduction in size of the tumor. DISCUSSION: It is important to achieve maximal resection of low-grade gliomas in children, lessening the need for adjuvant chemotherapy and radiotherapy, while minimizing the length of hospital stay and disruption to the child's life. Of our nine LGGs patients treated with this technology, six had undergone previous surgery and MRgLITT proved itself to be a safe surgical treatment option to achieve further cytoreduction. While most of the cases are pilocytic astrocytomas, the location of the tumors was surgically challenging. Eight of the nine cases required a single trajectory-laser-while our case example requires two lasers. Only a case of a midbrain-thalamic tumor presented a post-ablation significant brain edema as perioperative complication [1]. Eight of the nine tumors did not require any coadjuvant therapy or further surgical treatment to date. CONCLUSION: MRIgLITT is a successful option for treatment for selected de novo or recurrent low-grade gliomas in children. It can be combined with other therapies offering the advantages of a minimally invasive procedure. LITT may be added to the current pediatric neuro-oncology protocols, but larger prospective series are needed to show the effectiveness of LITT and to standardize indications and protocols.
BACKGROUND: Pediatric low-grade gliomas (LGGs) account for approximately half of all pediatric central nervous system tumors. The low-grade gliomas' first line of treatment is gross total resection. However, when gross total resection is not possible, options for adjuvant therapy are limited. MRI-guided laser ablation (magnetic resonance-guided laser interstitial thermal therapy (MRgLITT)) offers a new option for treatment in selected cases. We present a description of the current MRgLITT technology and an exemplary case-series review of our experience in its use in LGGs. CASE DESCRIPTION: A 19-month-old male was referred to the pediatric neurosurgery clinic with an incidental left temporal lesion discovered on a prenatal ultrasound. An MRI of the brain revealed a diffuse mesial temporal lesion. Electroencephalogram (EEG) showed generalized activity arising from the lesion. The patient underwent a navigation-guided biopsy then, two bolts were secured to the skull, and laser ablation was performed with intraoperative MR guidance. Pathology was consistent with ganglioglioma. Follow-up images 13 months after ablation showed a significant volumetric reduction in size of the tumor. DISCUSSION: It is important to achieve maximal resection of low-grade gliomas in children, lessening the need for adjuvant chemotherapy and radiotherapy, while minimizing the length of hospital stay and disruption to the child's life. Of our nine LGGs patients treated with this technology, six had undergone previous surgery and MRgLITT proved itself to be a safe surgical treatment option to achieve further cytoreduction. While most of the cases are pilocytic astrocytomas, the location of the tumors was surgically challenging. Eight of the nine cases required a single trajectory-laser-while our case example requires two lasers. Only a case of a midbrain-thalamic tumor presented a post-ablation significant brain edema as perioperative complication [1]. Eight of the nine tumors did not require any coadjuvant therapy or further surgical treatment to date. CONCLUSION:MRIgLITT is a successful option for treatment for selected de novo or recurrent low-grade gliomas in children. It can be combined with other therapies offering the advantages of a minimally invasive procedure. LITT may be added to the current pediatric neuro-oncology protocols, but larger prospective series are needed to show the effectiveness of LITT and to standardize indications and protocols.
Authors: Alexandre Carpentier; Roger J McNichols; R Jason Stafford; Jean-Pierre Guichard; Daniel Reizine; Suzette Delaloge; Eric Vicaut; Didier Payen; Ashok Gowda; Bernard George Journal: Lasers Surg Med Date: 2011-11-22 Impact factor: 4.025
Authors: David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison Journal: Acta Neuropathol Date: 2016-05-09 Impact factor: 17.088
Authors: Pinakin R Jethwa; Jason H Lee; Rachid Assina; Irwin A Keller; Shabbar F Danish Journal: J Neurosurg Pediatr Date: 2011-11 Impact factor: 2.375
Authors: Alexandre Carpentier; Roger J McNichols; R Jason Stafford; Julian Itzcovitz; Jean-Pierre Guichard; Daniel Reizine; Suzette Delaloge; Eric Vicaut; Didier Payen; Ashok Gowda; Bernard George Journal: Neurosurgery Date: 2008-07 Impact factor: 4.654
Authors: Richard Rammo; Karam Asmaro; Lonni Schultz; Lisa Scarpace; Salim Siddiqui; Tobias Walbert; Steven Kalkanis; Ian Lee Journal: J Neurooncol Date: 2018-03-13 Impact factor: 4.130
Authors: Kevin A Cross; Afshin Salehi; Mohamed S Abdelbaki; David H Gutmann; David D Limbrick Journal: Childs Nerv Syst Date: 2022-09-15 Impact factor: 1.532
Authors: Georgios P Skandalakis; Daniel R Rivera; Caroline D Rizea; Alexandros Bouras; Joe Gerald Jesu Raj; Dominique Bozec; Constantinos G Hadjipanayis Journal: Int J Hyperthermia Date: 2020-07 Impact factor: 3.914
Authors: Alexander A Hedaya; Kelsey C Hewitt; Ranliang Hu; Charles M Epstein; Robert E Gross; Daniel L Drane; Jon T Willie Journal: Epilepsy Behav Date: 2022-03-23 Impact factor: 3.337